ABSTRACT
PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein COVID-19 vaccine (NVX-CoV2373) demonstrated that the vaccine was safe and efficacious (vaccine efficacy, VE= 90%) for the prevention of symptomatic COVID-19. In the trial, participants were randomly assigned in a 2:1 ratio to receive 2 doses of NVX-CoV2373 or placebo 21 days apart. Throughout the study, SARS-CoV-2 circulating variant was predominantly alpha, but other variants circulated (i.e., beta, gamma, epsilon, and iota). VE among the per-protocol efficacy analysis population was calculated according to pre-specified disease severity (mild, moderate, or severe) criteria, but the impact on the risk of COVID-19– associated hospitalization was not specifically investigated. During the placebo-controlled portion of the trial (January 25, 2021, to April 30, 2021), 4 hospitalizations occurred among the 77 events analyzed for the primary endpoint using the per-protocol population, 0 among vaccine recipients and 4 among placebo recipients, yielding a VE against hospitalization of 100% (95% CI: 28.8, 100). Among an expanded efficacy population, which included COVID-19–associated hospitalizations without a requirement for diagnostic polymerase chain reaction testing performed at the study central laboratory, 12 total hospitalizations were identified, 0 among vaccine recipients and 12 among placebo recipients, yielding a post hoc VE against hospitalization of 100% (95% CI: 83.1, 100). These additional data from the PREVENT-19 trial provide relevant public health information concerning the attributes of NVX-CoV2373.
Competing Interest Statement
AMM, EU, XZ, JK, WW, AM, IC, HB, GA, ST, LMD are or were employees at the time of study conduct and might be shareholders of Novavax Inc.
Clinical Trial
NCT04611802
Funding Statement
This work was supported by Novavax, Inc. The PREVENT-19 study was supported by Novavax, Inc, the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) [contract number: OWS: Novavaxs Project Agreement No. 1 under its Medical CBRN Defense Consortium (MCDC) Base Agreement No. 2020-530; Department of Defense (DoD) No. W911QY20C0077] and the National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network (HVTN) Leadership and Operations Center [UM1 AI68614], the HVTN Statistics and Data Management Center [UM1 AI68635], the HVTN Laboratory Center [UM1 AI68618], the HIV Prevention Trials Network Leadership and Operations Center [UM1 AI68619], the AIDS Clinical Trials Group Leadership and Operations Center [UM1 AI68636], and the Infectious Diseases Clinical Research Consortium leadership group [UM1 AI148684]. Research, medical, and scientific support was provided by Sharon Glass of Novavax, Inc. Editorial support was provided by Kelly Cameron, PhD and Rebecca Harris, PhD of Ashfield MedComms (New York, NY), an Inizio company, supported by Novavax.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following Institutional Review Boards / Independent Ethics committees reviewed and gave ethical approval for the PREVENT-19 study: Western Copernicus Group IRB, US; Great Plains IRB, US; Comite de etica en investigacion del Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico; Comite de etica en investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C., Mexico; Comite de etica en investigacion del Instituto Nacional de Salud Publica, Mexico; Comite de etica en investigacion de Medica Rio Mayo S.C., Mexico; Comite de etica en investigacion del Hospital La Mision S.A. de C.V., Mexico. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Emails: AMM - AMarchese{at}Novavax.com; XZ - xizhou{at}Novavax.com; JK - jkinol{at}Novavax.com; EU - eunderwood{at}Novavax.com; WW – wwoo{at}Novavax.com; AM - amcgarry{at}Novavax.com; HB - HBeyhaghi{at}Novavax.com; GA – german.anez{at}gmail.com; ST - SToback{at}Novavax.com; LMD - LDunkle{at}novavax.com.
Data Availability
Study information is available at https://clinicaltrials.gov/ct2/show/ NCT04611802, and requests will be considered